Banca de QUALIFICAÇÃO: MARÍLIA VIRGO SILVA ALMEIDA

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : MARÍLIA VIRGO SILVA ALMEIDA
DATE: 05/12/2019
TIME: 09:00
LOCAL: A DEFINIR
TITLE:

EVALUATION OF INTESTINAL ANTI-INFLAMMATORY POTENTIAL OF LACTOBACILLUS PLANTARUM CNPC003 AND LACTOBACILLUS MUCOSAE CNPC007 PROBIOTICS IN MODEL OF DNBS-INDUCED INTESTINAL INFLAMMATION

KEY WORDS:

Intestinal inflammation; probiotics strains; sulfasalazine; inflammatory markers; oxidative stress

PAGES: 77
BIG AREA: Ciências Biológicas
AREA: Farmacologia
SUMMARY:

Inflammatory Bowel Disease (IBD), characterized by presenting an uncontrolled chronic inflammation in the intestinal mucosa, comprises mainly two conditions: Ulcerative Colitis (UC) and Crohn's Disease (CD). In these, the local immune system remains chronically activated and the intestine chronically inflamed due to an inability to decrease inflammatory responses. The production and release of reactive oxygen species (ROS) and proinflammatory cytokines by phagocytes play an important role in the pathophysiology of IBD. Failures and adverse effects of the drug options of choice have encouraged researchers to study effective therapeutic alternatives in reducing inflammatory symptoms, including probiotic bacteria. This research aimed to evaluate the intestinal anti-inflammatory activity of probiotics Lactobacillus plantarum CNPC003 (LP) and Lactobacillus mucosae CNPC007 (LM) in a model of experimental dinitrobenzenesulfonic acid (DNBS) induced colitis in rats. Thus, female Wistar rats (225-245 g) were divided into 5 experimental groups (n = 7): Healthy group: Healthy (S) that received saline solution; Collitic groups: DNBS control (DNBS) that received saline solution; and the probiotic-treated colitics: LP, LM and standard sulfasalazine drug (SSZ) at a dose of 250 mg / kg. The respective pretreatments of each group were administered by gavage for 17 days prior to induction of intestinal inflammation. After the 17th day treatments, colitis was induced by intracolonic administration of 30 mg DNBS (50% ethanol, v / v) and then the treatments were continued until the 19th day. On the 20th day, seventy-two hours after induction, all animals were euthanized. Macroscopic and microscopic parameters, inflammatory markers such as myeloperoxidase and tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), interleukin-β (IL-1β) cytokines, and oxidative stress (malondialdehyde) were evaluated. and intestinal barrier integrity mucin-2 (MUC-2) and occludin (OCL). Pretreatment with probiotics was able to attenuate the severity of colonic damage caused by DNBS, observed in the reduction of macroscopic damage score (p <0.05 vs. DNBS). This effect was associated with a significant reduction in myeloperoxidase (MPO) activity (p <0.05 vs. DNBS) and proinflammatory cytokine levels TNF-α and IL1β (p <0.05 vs. DNBS). . On the other hand, probiotics increased colonic levels of IL10, well-known as an anti-inflammatory cytokine. The beneficial effect of probiotics on DNBS-induced intestinal inflammation was also demonstrated by their ability to significantly reduce colonic oxidative stress, as observed by the reduction of malondialdehyde (MDA) (p <0.05 vs. DNBS). Additionally, LP and LM increased the expression of markers involved in epithelial integrity such as OCL and MUC-2. Thus, the probiotics LM and LP stand out for presenting an intestinal anti-inflammatory potential that could be an alternative in the prevention of IBD.

BANKING MEMBERS:
Presidente - 2330188 - GERLANE COELHO BERNARDO GUERRA
Interno - 2412258 - EDILSON DANTAS DA SILVA JUNIOR
Externo ao Programa - 3652554 - FRANCISCO CANINDE DE SOUSA JUNIOR